Early Life
The Boehringer Ingelheim story began in 1885, when Albert Boehringer purchased a small tartar factory in Ingelheim am Rhein, Germany. This marked the beginning of what would become a global pharmaceutical giant. Initially, the factory focused on producing tartaric acid for the food industry.
Rise to Success
A pivotal moment came in 1893 when Albert Boehringer discovered a method to mass-produce lactic acid using bacteria. This discovery spurred significant growth. The company was renamed C. H. Boehringer Sohn in honor of Albert's father. By the early 20th century, Boehringer Ingelheim expanded into pharmaceuticals, with the first drug, an analgesic, Laudanon, launched in 1912 and released to market in 1915. The company has since become a global enterprise.
Key Business Strategies
Boehringer Ingelheim's strategy involves a strong focus on research and development. The company invests heavily in R&D. A key aspect of their success is the private ownership structure, which allows for a long-term focus, shielded from the short-term pressures of public markets.
Philanthropy
In May 2000, Boehringer Ingelheim initiated a U.N./World Bank program to provide lower-priced HIV drugs to Africa, offering Viramune free of charge to developing countries for five years to prevent mother-to-child transmission. The company is involved in programs to improve stroke care.